Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa Topline results anticipated in the fourth quarter of 2021Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint...